JP2020510075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510075A5 JP2020510075A5 JP2019550800A JP2019550800A JP2020510075A5 JP 2020510075 A5 JP2020510075 A5 JP 2020510075A5 JP 2019550800 A JP2019550800 A JP 2019550800A JP 2019550800 A JP2019550800 A JP 2019550800A JP 2020510075 A5 JP2020510075 A5 JP 2020510075A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- acceptable salt
- therapeutic agent
- erα
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472345P | 2017-03-16 | 2017-03-16 | |
| US62/472,345 | 2017-03-16 | ||
| PCT/US2018/022961 WO2018170447A1 (en) | 2017-03-16 | 2018-03-16 | Combination therapies for the treatment of breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510075A JP2020510075A (ja) | 2020-04-02 |
| JP2020510075A5 true JP2020510075A5 (cg-RX-API-DMAC7.html) | 2021-04-30 |
| JP7219224B2 JP7219224B2 (ja) | 2023-02-07 |
Family
ID=61874039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550800A Active JP7219224B2 (ja) | 2017-03-16 | 2018-03-16 | 乳癌の治療のための組合せ療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11083722B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4218820A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7219224B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102517650B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110636862B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018234903B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019019261A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3056701A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL269357B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA47776A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019010981A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2764724C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201908531WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018170447A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109790141B (zh) * | 2016-11-28 | 2021-06-11 | 卫材 R&D 管理有限公司 | 吲唑衍生物的盐及其晶体 |
| WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| EP4240357A1 (en) * | 2020-11-06 | 2023-09-13 | Eisai R&D Management Co., Ltd. | Method of treating breast cancer |
| CN113018357A (zh) * | 2021-02-08 | 2021-06-25 | 湖南农业大学 | 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途 |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
| TR200402036T4 (tr) | 2000-01-18 | 2004-10-21 | Aventis Pharmaceuticals Inc. | (-)-Cis-2-(2-Klorofenil)-5, 7-Dihidroksi-8-[4R-(3S-Hidroksi-1-Metil) Piperidinil]-4H-1- Benzopiran-4-on'un psödopolimorfu |
| IL150643A0 (en) | 2000-01-18 | 2003-02-12 | Aventis Pharma Inc | Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 [4r-(3s-hydroxy-1-methyl) piperidinyl]-4h-1-benzopyran-4-one |
| WO2002022133A1 (en) | 2000-09-12 | 2002-03-21 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| EP1845974A1 (en) | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP1845973B1 (en) | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| WO2006077425A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
| JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| US7776832B2 (en) | 2006-04-21 | 2010-08-17 | Gem Pharmaceuticals, Llc | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| JP2009542608A (ja) | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
| EP2049106A2 (en) | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP2009543770A (ja) | 2006-07-14 | 2009-12-10 | アステックス・セラピューティクス・リミテッド | Cdk及びgskの阻害のためのピラゾール誘導体の組合せ剤 |
| EP2046327A1 (en) | 2006-07-21 | 2009-04-15 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| US20130035336A1 (en) | 2010-04-13 | 2013-02-07 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer |
| GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| KR102186969B1 (ko) | 2010-10-25 | 2020-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| KR101606250B1 (ko) | 2011-03-23 | 2016-03-24 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
| AU2013352406A1 (en) | 2012-11-28 | 2015-06-04 | Novartis Ag | Combination therapy |
| JP6430483B2 (ja) | 2013-03-15 | 2018-11-28 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 化学療法の間の正常細胞の一時的な保護 |
| EP4772247A2 (en) * | 2013-08-14 | 2026-07-08 | Novartis AG | Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer |
| SG11201607334YA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
| US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| MX384605B (es) * | 2015-04-29 | 2025-03-14 | Radius Pharmaceuticals Inc | Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. |
| RS62481B1 (sr) * | 2015-05-29 | 2021-11-30 | Eisai R&D Man Co Ltd | Jedinjenja tetrasupstituisanog alkena i njihova upotreba |
-
2018
- 2018-03-16 WO PCT/US2018/022961 patent/WO2018170447A1/en not_active Ceased
- 2018-03-16 EP EP23159590.1A patent/EP4218820A3/en not_active Withdrawn
- 2018-03-16 IL IL269357A patent/IL269357B2/en unknown
- 2018-03-16 AU AU2018234903A patent/AU2018234903B2/en active Active
- 2018-03-16 MX MX2019010981A patent/MX2019010981A/es unknown
- 2018-03-16 CA CA3056701A patent/CA3056701A1/en active Pending
- 2018-03-16 SG SG11201908531W patent/SG11201908531WA/en unknown
- 2018-03-16 BR BR112019019261-1A patent/BR112019019261A2/pt not_active Application Discontinuation
- 2018-03-16 US US16/493,931 patent/US11083722B2/en active Active
- 2018-03-16 RU RU2019132893A patent/RU2764724C2/ru active
- 2018-03-16 MA MA047776A patent/MA47776A/fr unknown
- 2018-03-16 KR KR1020197029851A patent/KR102517650B1/ko active Active
- 2018-03-16 JP JP2019550800A patent/JP7219224B2/ja active Active
- 2018-03-16 CN CN201880030008.9A patent/CN110636862B/zh active Active
- 2018-03-16 EP EP18715441.4A patent/EP3595725B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6575952B2 (ja) | イブルチニブ併用療法 | |
| JP2022160589A (ja) | Hivを治療するためのトール様受容体の調節因子 | |
| JP2026074095A (ja) | Hivウイルス感染症の予防的または治療的処置に有用な治療用化合物 | |
| RU2478387C2 (ru) | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR | |
| JP5547066B2 (ja) | 治療用組成物およびその使用 | |
| JP2017511360A5 (cg-RX-API-DMAC7.html) | ||
| JP5769762B2 (ja) | 治療組成物およびその使用 | |
| JP2013541595A5 (cg-RX-API-DMAC7.html) | ||
| JP2019511526A5 (cg-RX-API-DMAC7.html) | ||
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| KR20090013827A (ko) | Hiv 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ccr5 길항제 | |
| RU2600793C2 (ru) | Новый режим приема n-гидрокси-4-{2-[3-(n, n-диметиламинометил)бензофуран-2-илкарбониламино]этокси}бензамида | |
| JP2019511529A5 (cg-RX-API-DMAC7.html) | ||
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| JP2019528302A5 (cg-RX-API-DMAC7.html) | ||
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| RU2019132893A (ru) | Комбинированная терапия для лечения рака молочной железы | |
| JP2022525202A5 (cg-RX-API-DMAC7.html) | ||
| JP2012525391A5 (cg-RX-API-DMAC7.html) | ||
| PH12020552236A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| JP2021503448A5 (cg-RX-API-DMAC7.html) | ||
| CN101346137B (zh) | 含有孔布勒塔斯塔坦与抗癌剂的组合物 | |
| JP2018520102A (ja) | エベロリムスとダクトリシブとの薬学的組合せ | |
| JP2016530208A5 (cg-RX-API-DMAC7.html) |